FDG-PET is superior to amyloid PET imaging with the radiopharmaceutical florbetapir for assessing cognitive decline in patients with Alzheimer's disease or mild cognitive impairment. By Erik L. Ridley, AuntMinnie staff writer

“The differences that we observed indicate the strong possibility that there are sex differences in the structural and functional connections in the brain, which may contribute to women’s increased risk for Alzheimer’s,” said Sepideh Shokouhi, at the Alzheimer’s Association International Conference in Los Angeles. Matt O'Connor | Molecular Imaging | www.healthimaging.com

GCG Global Healthcare suggested reading: Amyloid PET imaging greatly influenced the clinical management of patients with mild cognitive impairment (MCI) and dementia, according to the first phase of a multicenter trial published April 2 in JAMA. The findings may have important implications for diagnosing and managing Alzheimer’s disease. By Matt O'Connor | Molecular Imaging

In PET imaging, the amount of radiotracer dose correlates with the level of image quality. But what if artificial intelligence (AI) could enable PET to be performed using only 1% of current dose levels -- speeding exam times, decreasing radiation exposure, lowering costs, and alleviating shortages in radiotracers? By Erik L. Ridley, AuntMinnie staff writer

A deep-learning algorithm that analyzed FDG-PET was able to differentiate between normal cognition and dementia by Wayne Forrest, AuntMinnie.com staff writer

Medical Benefits Reviews Task Group Diagnostic Imaging Review Team Department of Health and Ageing. As part of the 2009-10 Budget, the Australian Government announced a review of funding arrangements for diagnostic imaging, to ensure that the Government is paying the right amount in the right way to support access for patients to quality diagnostic imaging...